



SUBMISSION RULES & GUIDELINES FOR CVCT-LBCTs

Late-Breaking abstracts proposals are invited in the following areas:

- Primary and key secondary results of major clinical trials, at all stages (*from proof of concept to post-approval*) across the following therapeutic areas:
 - Cardiovascular
 - Kidney
 - Metabolism
- Abstracts should highlight Innovative therapies at all stages of development and advances in:
 - Drugs, devices, and biologics
 - Cell and gene therapies
 - Digital health, diagnostics, and AI in medicine
 - Trial methodologies and statistical approaches
- All submitted CVCT-LBCTs will be **automatically reviewed for ORAL PRESENTATION ONLY**.

A. SUBMISSION GUIDELINES

1. **Promissory** abstracts are accepted. Results may not necessarily be submitted if not known at the time of submission. Nevertheless, they need to be ready for presentation at the congress.
2. The **deadline** for submitting a CVCT-LBCT is **October 15, 2025, at 23:59 Central European Time (CET)**.
 - a. All submissions must be made via the online submission system.
 - b. No deadline extensions will be granted.
3. Abstract submitters are required to create an abstract submitter account by completing the [online form](https://www.globalcvctforum.com/) accessible via the conference website: <https://www.globalcvctforum.com/> before submitting an abstract.
4. **Draft Status:** If you do not complete the submission by clicking the "Submit" button, your abstract will remain in Draft Status. You may return to it and make changes at any time before the deadline. However, please note that any application still in draft status after the deadline will **not** be considered for selection.
5. **Changes and Corrections:** Once your submission has been completed and submitted, no further changes to the content or associated information (e.g., presenter details, topic selection) will be possible. If you need to make corrections, you must withdraw your original submission and resubmit a revised version before the deadline. *Note:* Replacing or editing your submission will not be permitted after the submission deadline.
6. **Withdrawal:** If you wish to withdraw a previously submitted Late-Breaking Science abstract, please notify us as soon as possible by emailing cvct-abstracts@overcome.fr. Be sure to include the **title** and **submission number** of the abstract to be withdrawn. Please note that withdrawal remains possible **even after the submission deadline**.

B. GENERAL GUIDELINES

1. Therapeutic Area

Select the most appropriate therapeutic area:

- Cardiovascular
- Kidney
- Metabolism

2. Topic:

Select the most appropriate topic:

- Drugs, devices, and biologics
- Cell and gene therapies
- Digital health, diagnostics, and AI in medicine
- Trial methodologies and statistical approaches

3. Theme:

Select the most appropriate theme (one or more themes can be selected):

1. Artificial Intelligence and digital therapeutics
2. Amyloidosis
3. Atherosclerosis
4. Atrial Fibrillation
5. Biologics
6. Biomarkers
7. Cardiomyopathies
8. Cell Therapy
9. CKD
10. Diabetes
11. Digital therapeutics
12. Electrophysiology and arrhythmias
13. Gene Therapy
14. Implementation Trials
15. Heart failure
16. Hypertension
17. Interventional cardiology -Valves
18. Interventional cardiology – Shock
19. Interventional cardiology – Structural
20. Interventional cardiology – Peripheral vascular
21. Thrombosis
22. MI - Post Mi
23. Obesity
24. Primary prevention
25. Pulmonary arterial hypertension
26. Real world evidence
27. Wearables

4. Abstract title

- a. Full title – 200 characters maximum, in lower case, except for abbreviations
- b. In lower case, a short, specific title (containing no abbreviations or inflammatory language) that indicates the nature of the investigation.
- c. Your title may be truncated if you copy and paste it—please review it carefully after pasting.

5. Acronyms

If your study is known by an acronym, please enter both the acronym (e.g., *CVCT*) and its full name (e.g., *CardioVascular Clinical Trials*) in this field. If irrelevant, please indicate N/A

6. Author & Affiliation Requirements

- a. The submission must include at least 1 author.
Additional authors may be added using the **"Add new co-author"** button, where you can enter each author's name and affiliation.

It is mandatory to include all affiliations, including city and country to each author entry.

- b. The **First Author** must appear **first** in the author list.
- c. The Presenter must be clearly identified by selecting the **'Presenter'** checkbox next to their name.
- d. If the **First Author** or **Presenter** is **not the Corresponding Author**, you must designate the Corresponding Author by checking the appropriate box.

Important: The submitter confirms that they have obtained permission from all individuals listed as co-authors to include their names in the submission. If none of the listed authors are available to present at the congress, the application must be withdrawn.

7. **Conflict of Interest:** Conflicts of interest must be declared. Full details can be found in [*section D. Submission Rules below.*](#)

8. Abstract Content

- a. All abstracts must be submitted in English with proper grammar and spelling suitable for publication.
- b. **Important formatting note:** Please do not copy and paste symbols into your text. Use the symbol provided by clicking the Ω button within the submission system.
- c. The abstract should be structured using the following sections:
 - **Background:** Briefly provide relevant context and the purpose of the study, ideally in one or two sentences.
 - **Methods:** Concise description of the methods used. For trials without available results, include information on endpoints and statistical power if possible.
 - **Results:** Summarize the results with enough detail to support the conclusions. If results are not available, this section should still provide as much relevant information as possible.
 - **Conclusions:** Clearly state the conclusions drawn from the study. Phrases such as "the results will be discussed" are not acceptable.

If results are not yet available, please describe the main endpoints you expect to report and the conclusions you anticipate based on the study design.

C. TECHNICAL GUIDELINES

1. Maximum size:

- a. **Title:** up to 200 characters, in lower case, except for abbreviations
- b. **Abstract content:** Cannot exceed 3800 characters, including tables (not including the title / images)
Abstract text and spaces will be counted.

2. Images: Up to three images can be added and must adhere to the following:

- a. Format PNG, BMP, GIF, JPG, JPEG.
- b. Maximum size 3MB
- c. 1800 pixels x 1000 pixels
- d. The image title field is mandatory and limited to 50 characters.

3. Image Submission Responsibility

- a. Submitters are fully responsible for the images they upload. Please ensure that all images are correctly uploaded and clearly visible in the abstract preview, as this reflects how reviewers will see them.
- b. It is the submitter's responsibility to verify that the quality of all attachments is adequate. Images that are unclear or of insufficient quality may be subject to deletion.

4. Final Submission Checklist:

- a. Please review your abstract in preview mode carefully before submitting, as no changes can be made after submission.
- b. Upon finalizing by clicking the "submit button" you confirm that your abstract:
 - I. **Has not been previously published or presented.**
 - II. You have read and accepted the submission and presentation rules (see below for full details).

To confirm that your abstract has been successfully submitted, you will receive an automatic email confirmation. Should you not receive this confirmation, please email cvct-abstracts@overcome.fr

D. SUBMISSION RULES

1. **Number of submissions:** There is no limit to the number of Late-Breaking Science applications an author may submit. If two abstracts are submitted with the same research, even under different themes and topics, we will automatically retain and consider the most recent version. Duplicate drafts **will not be automatically deleted but will not be considered for review.**
2. **Embargo and Publication**
 - a. All accepted abstracts are subject to an embargo until they are officially released by CVCT Forum. Authors and co-authors must not share, present, or publish any part of the abstract or its data prior to the embargo lift.
 - b. The embargo will be lifted at a date and time to be communicated by the CVCT Scientific Program Committee. Until then, no abstract content may be disclosed publicly through media, social platforms, institutional press releases, or conference presentations.
3. **Simultaneous publications:** The submission of research that is under consideration for publication or presentation at other venues concurrently with the CVCT is encouraged. For instance, a study may be submitted to the CVCT while simultaneously undergoing peer review for publication in a scientific journal. This policy facilitates the timely dissemination of significant scientific findings to a broad audience. CVCT has developed a privileged track with **expedited review with the Journal of the American College of Cardiology (JACC). LBCTs submitters are encouraged to submit their work for simultaneous publication at JACC.**
4. **Encore Abstracts:** Please note that encore abstracts—those that have been previously presented or published elsewhere—will not be considered as an CVCT-LBCT. All submissions must represent original work that has not been publicly disclosed or presented at other conferences.
5. **Consent and Acceptance:**
 - a. By submitting an abstract, authors **consent to its publication upon acceptance.** If accepted, authors will be asked to **review and approve the final version** before it is published.
 - b. Once the embargo is lifted (D2.1 above), accepted abstracts may be published in, but are not limited to:
 - The **CVCT 2025 Program-At-a-Glance**
 - The **CVCT Forum website**
 - **Conference materials**
 - The **CVCT Forum Congress archives**
6. **Accepted abstracts:**
 - a. By submitting an CVCT-LBCT, author(s) agree to present the abstract **in person in Washington during the 2025 CVCT Forum** if accepted.
 - b. Abstracts will be **withdrawn** from the scientific program if the presenting author does not complete **registration, submit required presentation materials by the set deadlines.**
 - c. **All costs** related to participation—including travel, accommodation, and registration—are the **sole responsibility of the presenter.**

- d. Should unforeseen or exceptional circumstances arise, the CVCT Forum retains the right to **adjust presentation requirements** and will communicate any changes directly to the affected presenters.
- 7. **Withdrawal:** In exceptional circumstances, withdrawal is possible by notifying cvct-abstracts@overcome.fr **before October 30, 2025 at the very latest.**
- 8. **Copyright**
 - a. By submitting an CVCT-LBCT, the submitter confirms that the content is original, except for any portions taken from copyrighted materials with full permission from the rights holders. All factual claims included have been thoroughly verified for accuracy.
 - b. Submission to the CVCT implies consent for the authors' names, affiliations, and biographical details to be used in relation to the publication of the work.
 - c. The author(s) declare that they are the sole creators of the work, that all listed authors have contributed to and approved the content and conclusions, and that the work does not violate any third-party copyrights, proprietary rights, or personal rights.
 - d. Submitting work that has already been published or presented elsewhere may affect eligibility for future submissions.
- 9. **Conflict of Interest**
 - a. The CVCT Scientific committee requires that all **presenters** disclose any potential conflicts when submitting a CVCT-LBCT in the appropriate section. If there are no conflicts to declare, please insert ***"The authors declare no conflicts of interest."***
 - b. Presenters are also responsible for ensuring that any potential conflicts of interest involving their co-authors related to the presentation are clearly disclosed during the presentation itself, if applicable. This transparency enables the audience to consider these factors when evaluating the impartiality of the information presented.
 - c. Potential conflicts of interest can arise from various past or current relationships, including but not limited to: employment, consulting roles, investments or stock ownership, research funding, or familial connections. All such relationships must be fully declared.
 - d. This includes associations with pharmaceutical companies, medical device manufacturers, or other organizations whose products or services are relevant to the subject matter. Examples of relevant relationships include employment, stock ownership, membership on advisory boards or committees, board directorships, or any public affiliation with a company or its products.
 - e. Other situations that may present a real or perceived conflict include receiving honoraria, consulting fees, research grants, or other financial support from such companies or their representatives.

E. CVCT-LBCT SELECTION AND COMMUNICATION OF RESULTS

1. Review Period

- a. After the submission deadline, all submitted CVCT-LBCTs will be sent to the review committee. Changes will not be possible during the review period, no changes to the abstracts will be permitted during the review period. However, withdrawal of abstracts remains possible by contacting: cvct-abstracts@overcome.fr.
- b. Corresponding authors will be informed of the outcome of their submissions via email by **November 15, 2025**. Notification will specify whether the abstract has been:
 - I. Accepted: CVCT-LBCT Oral Presentation
 - II. Rejected
- c. If the abstract is accepted, detailed instructions regarding presentation schedules and guidelines will be sent directly to The Presenter as listed on the submission form.